Cuprina Holdings (Cayman) Limited stock traded little changed on Monday as investors digested last week's compliance-driven rally that sent the biomedical company's shares sharply higher. The stock was down 1.76% at $3.90 during premarket trading, following a breakout session on Friday where CUPR soared 64.73% to close at $3.97. With a small public float, Cuprina can experience outsized price swings, as modest changes in retail trading volume often trigger sharp rallies or steep pullbacks.

The surge came after Cuprina announced it had regained compliance with Nasdaq Capital Market listing requirements, removing the risk of delisting. Nasdaq's Listing Qualifications staff informed the exchange's Hearings Department that Cuprina satisfies the minimum bid price requirement and is fully compliant with Nasdaq Capital Market rules. Consequently, a hearing before the Nasdaq Hearing Panel scheduled for July 7, 2026, has been cancelled.

Cuprina had received a Staff Delisting Determinations Letter on May 29, 2026, after its securities closed below $1.00 for 30 consecutive business days. The company failed to regain compliance within the initial 180-day grace period under Listing Rule 5810(c)(3)(a). In response, Cuprina appealed the determination and requested a hearing under Listing Rule 5815 to stay any suspension pending the appeal.

Compliance Timeline

"We are gratified to regain compliance with Nasdaq," said CEO David Quek. He added that the company looks forward to continuing its initiatives to grow Cuprina's business in multiple biomedical sectors. Cuprina develops and markets products for chronic wounds, infertility, medical waste recycling, and cosmeceuticals.